Compare · CHE vs STLN
CHE vs STLN
Side-by-side comparison of Chemed Corp (CHE) and Starling Oncology Inc. (STLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CHE and STLN operate in Medical/Nursing Services (Health Care), so they compete in similar markets.
- CHE is the larger of the two at $7.13B, about 20.0x STLN ($357.0M).
- CHE has been more active in the news (15 items in the past 4 weeks vs 10 for STLN).
- CHE has more recent analyst coverage (8 ratings vs 0 for STLN).
- Company
- Chemed Corp
- Starling Oncology Inc.
- Price
- -
- -
- Market cap
- $7.13B
- $357.0M
- 1M return
- +6.71%
- -
- 1Y return
- +26.14%
- -
- Industry
- Medical/Nursing Services
- Medical/Nursing Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 15
- 10
- Recent ratings
- 8
- 0
Chemed Corp
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates in two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned branches and independent contractors, and franchised locations. Chemed Corporation was incorporated in 1970 and is headquartered in Cincinnati, Ohio.
Starling Oncology Inc.
Founded in 2007, Starling Oncology, Inc. (Nasdaq: STLN) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. Formerly known as The Oncology Institute, Starling Oncology offers cutting-edge, evidence-based cancer care to a population of approximately 2.2 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 400 employed and network clinicians and over 100 clinics and network locations of care across five states and growing, Starling Oncology is coordinating cancer care for the better.
Latest CHE
- Executive vice president Lee Spencer S sold $547,610 worth of Capital Stock (1,000 units at $547.61), decreasing direct ownership by 7% to 12,931 units (SEC Form 4)
- Chemed Corporation Declares Quarterly Dividend of 70 Cents
- President and CEO Mcnamara Kevin J sold $1,075,800 worth of Capital Stock (2,000 units at $537.90), decreasing direct ownership by 2% to 82,220 units (SEC Form 4)
- Executive vice president Lee Spencer S sold $494,196 worth of Capital Stock (920 units at $537.17), decreasing direct ownership by 6% to 13,931 units (SEC Form 4)
- Chemed Corporation to Present at the UBS 2026 Global Healthcare Conference
- SEC Form 10-Q filed by Chemed Corp
- Chemed upgraded by Jefferies with a new price target
- SEC Form 8-K filed by Chemed Corp
- Chemed Reports Third-Quarter 2026 Results
- SEC Form 4 filed by Chemed Corp
Latest STLN
- Amendment: SEC Form SCHEDULE 13G/A filed by Starling Oncology Inc.
- Amendment: Large owner Chernett Jorey acquired $1,113 worth of Call Option (1,391 units at $0.80) (SEC Form 4)
- SEC Form 25-NSE filed by Starling Oncology Inc.
- Amendment: Starling Oncology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Large owner Chernett Jorey acquired $1,113 worth of Call Option (1,391 units at $0.80) (SEC Form 4)
- Starling Oncology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Large owner Chernett Jorey sold $11,375,733 worth of shares (2,851,061 units at $3.99) and bought $176,273 worth of shares (48,294 units at $3.65), decreasing direct ownership by 26% to 7,858,091 units (SEC Form 4)
- SEC Form 10-Q filed by Starling Oncology Inc.
- Starling Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance